Traws Pharma filed a prospectus for a mixed shelf offering with an aggregate offering price of up to $139,185,641.25. The filing allows the company to offer and sell a combination of common stock, preferred stock, debt securities, warrants, or units in one or more offerings. The specific terms of any securities offered will be detailed in a prospectus supplement at the time of sale.

The securities may be offered at fixed prices, market prices, or negotiated prices. Sales may be conducted through underwriters, dealers, agents, or directly to purchasers on a continuous or delayed basis. The prospectus supplement will outline the specific distribution plan and may update information contained in the base prospectus.

Traws Pharma's common stock is currently listed on The Nasdaq Capital Market under the symbol "TRAW." On June 29, 2026, the last reported sale price of the common stock was $0.82 per share. The prospectus cannot be used to offer or sell securities unless accompanied by a supplement.

Securities Offered

The prospectus covers the following types of securities:

The aggregate offering price of all securities sold under this prospectus may not exceed $139,185,641.25. Investors are advised to review the prospectus and any supplements carefully before purchasing securities.

Traws Pharma is developing an updated toxicology data package to address information requirements from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) for the planned Phase 2a human influenza challenge study of tivoxavir marboxil (TXM). The company expects to resubmit the data package to the MHRA during the third quarter of 2026. Following the resubmission, Traws Pharma anticipates a formal response from the regulatory body within 30 days.

The decision follows detailed feedback received from the MHRA after Traws’ announcement on June 12, 2026. The company believes the updated package will support the proposed seasonal influenza challenge study in healthy volunteers and provide proof of concept data for TXM’s use as an oral prophylaxis medicine. Iain D. Dukes, MA, DPhil, Chief Executive Officer of Traws Pharma, expressed confidence that the additional preclinical safety information would meet the agency's requirements.

C. David Pauza, PhD, Chief Science Officer of Traws Pharma, noted that TXM demonstrated broad in vitro efficacy across multiple strains of seasonal influenza. He highlighted the product candidate's pharmacokinetic profile as consistent with its use as a chemoprophylactic agent. Concurrently, the company will initiate profiling of additional molecules for advancement in its influenza treatment program.

Robert R. Redfield, MD, Chief Medical Officer of Traws Pharma, emphasized the continued threat of seasonal influenza to public health in the US and worldwide. He stated that treatment and prevention are particularly critical for vulnerable populations, including the elderly and immunocompromised individuals who are at a much greater risk for severe influenza compared to the general population.

Key Program Details